Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

J. Letreut



Author of

  • +

    P3.02b - Poster Session with Presenters Present (ID 494)

    • Event: WCLC 2016
    • Type: Poster Presenters Present
    • Track: Advanced NSCLC
    • Presentations: 1
    • +

      P3.02b-127 - NSCLC Patients Harboring HER2 Mutation: Clinical Characteristics and Management in Real World Setting. EXPLORE GFPC 02-14 (ID 4629)

      14:30 - 14:30  |  Author(s): J. Letreut

      • Abstract

      Background:
      HER 2 (Human epidermal growth factor 2) mutation (exon-20 insertion) is a rare oncogenic driver in Non Small Cell Lung Cancer (NSCLC) (1%) and few data are published on the management of these patients outside patients included in clinical trial. Objective: to investigate clinical characteristics and management of these patients in real world setting

      Methods:
      multicentric inclusion of pts with a diagnosis of NSCLC harboring HER 2 mutations between January 2012 and December 2014, collection of demographic and clinical characteristics, risk factors, Progression free survival (PFS), Overall Survival (OS), mode of progression and therapeutic management

      Results:
      30 patients recruited in 17 centers: 20 (66,6%) female; age: 65,2 ± 12,1 years; PS 0/1 at diagnosis: 92,5 %; current/former smokers: 0/8(27,6%); adenocarcinoma: 93,3%; Stage at diagnosis 4-3/2-1: 93.1%/6,9%: co-mutations ALK n=1, RET n=1. Two-years overall survival (OS) 44,0% [CI :27,1 ; 71,5%] (early stage : 2-years OS : 100%). Management and Outcomes of stage IV (n=22): 82% received a first line platin based doublets With an overall response rate (ORR) and Progression Free Survival (PFS) of 61,5%, and 6.7 months (CI 5.6 ;19.0); 55% received a . second line treatment with an ORR and PFS of 36,4% and 3,4 months (CI 1,8;12,7); Two-years-OS was 27,2 %(CI:11,7;63,2%) and median OS survival 10,7 months (CI not research). .

      Conclusion:
      In this real world analysis, the majority of NSCLC patients with HER2 mutation were women, nonsmokers, adenocarcinoma and appears to have a same survival that NSCLC patients without oncogenic driver. Clinical trial information: Supported by an academic grant from Lilly, Astra Zeneca, boehringer ingelheim